Slow Progress with Scleroderma
Authors: M. ERIC GERSHWIN
Journal: Annals of Internal Medicine (1982)

Editorials1 November 1982Slow Progress with SclerodermaM. ERIC GERSHWIN, M.D.M. ERIC GERSHWIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-97-5-776 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn two decades, immunology has expanded with astounding speed: the decade of the lymphocyte (1960s) and the decade of genetic control of immune responsiveness (1970s). The 1980s will probably be the decade of monoclonal antibodies. During this period of growth and differentiation, rheumatology has also developed exponentially by taking advantage of this new knowledge. Progress in immunologically mediated rheumatic diseases has been both substantial and gratifying; there has generally been only a short lag between discoveries in basic immunology to their being applied by rheumatologists in in-vitro and in-vivo models of clinical immunologic disease. Increased knowledge and refinement of data...References1. HAYNESGERSHWIN DM. The immunopathology of progressive systemic sclerosis. Sem Arth Rheum. 1982;11:331-51. CrossrefMedlineGoogle Scholar2. TANRODNANGARCIAMOROIFRITZLERPEEBLES EGIYMC. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980;23:617-25. CrossrefMedlineGoogle Scholar3. KONDORABINRODNAN HBG. Cutaneous antigen-stimulating lymphokine production by lymphocytes of patients with progressive systemic sclerosis (scleroderma). J Clin Invest. 1976;58:1388-94. CrossrefMedlineGoogle Scholar4. KORNHALUSHKALEROY JPE. Mononuclear cell modulation of connective tissue function: suppression of fibroblast growth by stimulation of endogenous prostaglandin production. J Clin Invest. 1980;65:543-54. CrossrefMedlineGoogle Scholar5. TAJIMAPINNELL SS. Collagen synthesis by human skin fibroblasts in culture: studies of fibroblasts explanted from papillary and reticular dermis. J Invest Dermatol. 1981;77:410-2. CrossrefMedlineGoogle Scholar6. MARICQLEROYD'ANGELO HEW. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum. 1980;23:183-9. CrossrefMedlineGoogle Scholar7. KAHALEHSHERERLEROY MGE. Endothelial injury in scleroderma. J Exp Med. 1979;149:1326-35. CrossrefMedlineGoogle Scholar8. GERSHWINABPLANALPCASTLES MHJ. Characterization of a spontaneous disease of white Leghorn chickens resembling progressive systemic sclerosis (scleroderma). J Exp Med. 1981;153:1640-59. CrossrefMedlineGoogle Scholar9. STEENMEDSGERRODNAN VTG. D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med. 1982;97:652-9. LinkGoogle Scholar10. LOPEZ-OVEJEROSAALD'ANGELOCHEIGHSTENZELLARAGH JSWJKJ. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med. 1979;300:1417-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByScleroderma as a Fibrotic DisorderA controlled trial of antihypertensive therapy in systemic sclerosis (scleroderma). 1 November 1982Volume 97, Issue 5Page: 776-778KeywordsClinical immunologyGeneticsImmunologyLymphocytesMonoclonal antibodiesRheumatologyScleroderma Issue Published: 1 November 1982 PDF DownloadLoading ...